DeepMind’s AlphaGenome Atlas precomputes molecular effects for about nine billion possible single-letter DNA changes and ranks them with AVI scores. A research traffic map, not a clinical diagnosis.
A mouse and cell study links rapamycin with lower atrial fibrillation susceptibility in an accelerated-aging model, pointing to HIF-1α and mitochondrial metabolism. The findings are mechanistic clues, not proof of human benefit or a reason to self-medicate.
Human SFEMG and rodent work in JCI 2026 show sarcopenic weakness can come from postsynaptic NaV1.4 loss at the NMJ, not just wasting. Partial ClC-1 inhibition restored transmission-related force in aged rats; this is not a human drug claim.
Nature Biotechnology embeds six proteomic aging clocks in a phase 2a rentosertib IPF trial. Treated arms show concordant biological-age reductions peaking at week 4, partly dissociated from FVC gains. A dual-purpose design demo, not proof of rejuvenation.
GLP-1 receptor agonist semaglutide reverses high-fat diet-induced hippocampal microglia activation via the IGFBPL-1/PI3K/AKT pathway in mice. This article explores the molecular bridge from gut hormones to brain protection — and the gap between animal data and clinical reality.
The elderly need autologous stem cell therapy most, yet their stem cells are few and worn out. A 2026 Scientific Reports study briefly treated aged fat-derived stem cells with rapamycin plus nicotinamide, lowering p16, p21 and inflammatory cytokines while restoring differentiation by rebooting the stalled AMPK-mTOR-autophagy loop.